Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience

被引：0
|
作者：
Mare, M. [1 ]
Munao, S. [1 ]
Germana, S. [1 ]
Colarossi, C. [1 ]
Sciacca, D. [1 ]
Giuffrida, D. [1 ]
Giannone, G. [1 ]
机构：
[1] Mediterranean Inst Oncol, Div Med Oncol, Viagrande, CT, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D30
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
    Barrera, Ivan
    Filimon, Sabin Dragos
    Meng, Jassy
    Kavan, Tomas
    Rho, Young Soo
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [22] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer
    Lim, Alexander
    Kim, Dae Won
    Kim, Kunhwa
    Kim, Richard D.
    Bottiglieri, Salvatore Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [24] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
    You, Min Su
    Ryu, Ji Kon
    Kang, Jinwoo
    Choi, Jin Ho
    Choi, Young Hoon
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
  • [25] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [26] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [27] Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites
    Inoue, Kanae
    Fukushi, Koh
    Yamaguchi, Shota
    Taira, Tomonao
    Shibuki, Taro
    Satake, Tomoyuki
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Imaoka, Hiroshi
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    PANCREATOLOGY, 2024, 24 (04) : 616 - 623
  • [28] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [29] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [30] Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience
    A. E. Quinton
    S. H. Gwynne
    K. L. Yim
    Medical Oncology, 2018, 35
12345